I. Legal Background and Regulatory Guidance Framework

In dissolution testing of pharmaceutical solids, the pretreatment of the dissolution medium is a crucial preliminary step that determines fluidic reproducibility and reduces inter-cup variability (%CV). Microbubbles significantly alter the flow field, disrupt the boundary layer, and cause buoyancy interference to the formulation at the physical level, leading to unexpected test deviations (OOS/OOT). Major international regulations and guidelines have clear specifications for media degassing:

1. USP <711> Dissolution : The official standard degassing method (heated filtration) is included in the Procedure section.

2. USP <1092> The Dissolution Procedure: Development and Validation : The section on method development details the sensitivity assessment of dissolved gases in the medium to the dissolution of different formulations, the validity of the degassing method, and its impact on analytical detection.

3. USP Dissolution Toolkit (Version 2.0) : Clearly defines the degassing quantification acceptance standard (dissolved oxygen specification) when performing physical and chemical performance verification (PVT) of the dissolution system.

4. Ph. Eur. 2.9.3 / JP 15 / Chinese Pharmacopoeia Ninth Edition : consistently requires appropriate degassing of the medium for gas-sensitive preparations to ensure the authenticity of in vitro dissolution behavior.

II. USP <711> Official Standard Degassing Procedure (Compendial Method)

USP <711> specifies the following standard degassing procedure:

1. Heating : Heat the prepared dissolution medium to approximately 41°C to 45°C while gently stirring.

2. Vacuum Filtration : Passing the hot material through a microporous membrane with a pore size of 0.45 µm (or an appropriate pore size) using a depressurized (vacuum) method.

3. Continuous negative pressure stirring : After filtration is complete, maintain the vacuum depressurization state and continue to stir gently for about 5 minutes .

4. Isothermal Dispensing : Cool the medium back to the test operating temperature ( 37.0 ± 0.5°C ) and slowly dispense it into each dispensing vessel.

III. Four Major Disruptive Mechanisms of Incomplete Degassing in Dissolution Tests

Excess dissolved gases (N2, O2, CO2) in the medium release microbubbles when heated to 37°C and stirred, causing the following systemic disturbances:

1. Changes in effective contact area of the preparation surface and abnormal buoyancy :

   • Microbubbles adsorb onto rough areas of the tablet surface, forming air pockets that alter the sedimentation geometry of the sample at the bottom of the cup and may even cause the tablet to float.

   • Bubbles prevent the solid-liquid contact between the medium and the main component (API), significantly reducing the effective dissolution surface area (S), resulting in a lag in the dissolution curve and a falsely low dissolution amount.

2. Air Lock in Apparatus 1 :

   • In the basket method, microbubbles are easily trapped in the 40 mesh, forming an air barrier that hinders the natural convection of the medium inside and outside the cup, preventing the dissolution liquid in the basket from diffusing smoothly.

3. Damage to the Nernst-Brunner Boundary Layer :

   • According to the Nernst-Brunner equation:

   • When bubbles adhere to the paddle or escape upwards, they disrupt the symmetrical laminar flow inside the cup, causing random fluctuations in the diffusion layer thickness $h$, resulting in a sharp increase in the inter-cup variation coefficient (%CV / %RSD).

4. Automatic sampling and detection interference :

   • If a bubble gets stuck in the automatic sampling line or needle filter, it will increase fluid resistance and cause inaccurate sampling volume.

   • When passing through an online UV-Vis flow cell or fiber optic probe, bubbles cause intense light scattering, producing artifact spikes.

IV. Quantitative Monitoring Indicators for Dissolved Oxygen (DO)

The absence of visible bubbles is insufficient as a compliant release criterion; modern regulations require dissolved oxygen levels as the quantitative basis.

1. USP Toolkit Quantization Threshold :

   • The dissolved oxygen (DO) of the degassed medium must reach < 6.0 mg/L (or < 6.0 ppm) .

   • At 37°C, the atmospheric equilibrium saturation dissolved oxygen is approximately 6.8 - 7.5 mg/L, and compliant degassing procedures typically require reducing dissolved oxygen saturation to below 40% - 50% .

2. The high dependence of PVT (Protection for Chemical Properties) on degassing :

   • The official standard USP Prednisone Tablets RS are highly air-sensitive.

   • If the medium is not degassed (DO ≥ 6.0 mg/L), the disintegrating particles of phenylephrine tablets are easily disturbed by microbubbles, forming irregular cones, which leads to a serious deviation in the 30-minute dissolution geometric mean (GM), and the %CV can easily exceed the regulatory limits (e.g., > 4.9% or > 6.7%), causing PVT failure.

V. Comparison of the characteristics of various degassing technologies

VI. Degassing Strategies for Media Containing Surfactants

BCS Class II/IV poorly soluble drugs often require the addition of surfactants such as sodium lauryl sulfate (SLS/SDS) and Tween 20/80. Because negative pressure vacuum can cause violent foaming and backflow, the standard operating procedure is as follows:

1. "Pre-deaeration then Spike" is the regulatory-recommended best practice .

   • First, take approximately 90%–95% of the volume of pure water or buffer solution and fully execute the USP official standard heated filtration and degassing procedure.

   • Add the pre-weighed surfactant (or concentrated mother liquor) to the degassed medium.

   • It employs a low-speed, gentle magnetic stirring and dissolution method that is vortex-free, eliminating the risk of foaming and secondary oxygenation caused by violent disturbances.

2. Anti-foam vacuum ramping :

   • An automated system with pressure easing program control can perform pressure-controlled degassing of solutions containing low concentrations of SLS (e.g., ≤ 0.5% to 1.0%) under a specific negative pressure curve.

VII. Instrument Hardware and Data Integrity Requirements

Modern solvent preparation and degassing systems that comply with regulations and standards must meet the following indicators:

• Volumetric accuracy : Dispensing capacity error must be less than or equal to ±1.0% (gravimetric accuracy of ±0.5%, volumetric accuracy of ±0.8%).

• Continuous temperature monitoring : Real-time monitoring of the temperature of the heating chamber and the liquid outlet of the dispensing gun, with the liquid outlet temperature precisely maintained at 37.0 ± 0.5°C , to avoid test delays caused by temperature differences inside the cup.

• Dispensing channel prevents microbubble entrainment : It has a submersible anti-drip injection gun tube that guides the liquid to flow slowly along the dissolution cup wall, avoiding the generation of secondary bubbles due to impact.

• Data integrity regulations : The hardware and software must comply with FDA 21 CFR Part 11 and ALCOA+ principles , including multi-level account access management, tamper-proof audit trails, formula management (degassing, heating temperature, dispensing volume settings), and complete batch dispensing report output.

VIII. Qinwei Technology Perspective

Degassing of the solvent medium is not only a pretreatment step in routine solvent separation tests, but also a core control point for ensuring the successful completion of chemical performance testing (PVT) and reducing the incidence of analytical errors (OOS/OOT). Chinwei Technology possesses extensive experience in mechanical verification (MQ) and fluid dynamics calibration of solvent separators, and can provide mobile, fully automated solvent degassing and dispensing integrated solutions (such as Logan MDS-700 / Pharma Test PT-DDS4) that fully comply with USP <711>, USP <1092>, and USP Toolkit specifications. This fundamentally eliminates microbubble interference, helping your laboratory establish highly reproducible and cGMP-compliant analytical standards from R&D to QC.

IX. References and Sources

• USP <711> — Dissolution.

• USP <1092> — The Dissolution Procedure: Development and Validation.

• USP Dissolution Toolkit (Version 2.0) — Procedures for Mechanical Verification and Performance Verification Test (PVT) for Apparatus 1 and Apparatus 2.

• Ph. Eur. 2.9.3 — Dissolution Test for Solid Dosage Forms.

• US FDA Guidance for Industry — The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practice (CGMP) (2010).

• Chinese Pharmacopoeia, Ninth Edition —Part V: General Examination Methods, Guidelines on the Method for Testing the Dissociation of Preparations.